日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)

针对共同的非突变抗原和共同的突变BRAF新抗原的黑色素瘤疫苗的I/II期临床试验,采用激动性CD40抗体(CDX-1140)和TLR3激动剂(poly-ICLC)

Ninmer, Emily K; Petroni, Gina R; Gastman, Brian R; Gaughan, Elizabeth M; Isaacs, James M; Haden, Kathleen; Kaur, Varinder; Wages, Nolan A; Chianese-Bullock, Kimberly A; Smith, Kelly T; Wright, Paul; Bryant, Jennifer; Dunlap-Brown, Marya; Engel, Jack A; Bekiranov, Stefan; Mauldin, Ileana S; Truong, Thach-Giao; Bullock, Timothy N J; Slingluff, Craig L Jr

Patterns and Predictors of Sentinel Lymph Node Biopsy Utilization in High- and Low-Risk Thin Melanomas

高危和低危薄层黑色素瘤前哨淋巴结活检利用模式及预测因素

Mayhew, Mackenzie M; Tocco, Emily G; Mercante, Margaret G; Kuchimanchi, Nidhi; Shen, Chengli; Moheb, Mohamad El; Ruff, Samantha; Dengel, Lynn T; Slingluff, Craig L Jr; Witt, Russell G

Evaluation of Antibodies Induced by Melanoma Helper Peptide Vaccine and Their Modulation by Vaccine Adjuvants

黑色素瘤辅助肽疫苗诱导抗体的评价及其受疫苗佐剂的调节

Ashkani, Emily G; Dickinson, Anna M; Olson, Walter C; Taylor, Justin J; Slingluff, Craig L Jr

Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

随机 I/II 期临床试验,评估黑色素瘤辅助肽疫苗联合或不联合全身性激动性抗 CD27 抗体(Varlilumab)的疗效

Ninmer, Emily K; Petroni, Gina R; Gaughan, Elizabeth; Poklepovic, Andrew S; Kaur, Varinder; Haden, Kathleen; Chianese-Bullock, Kimberly A; Smith, Kelly T; Wright, Paul; Bryant, Jennifer L; Brighton, David; Engel, Jack A; Bullock, Timothy N J; Slingluff, Craig L Jr

Immunotherapy Administration and Survival for Stage IV Melanoma Patients at Minority-Serving Hospitals

少数族裔服务医院中IV期黑色素瘤患者的免疫疗法实施与生存率

Mayhew, Mackenzie M; Hemmer, Zoe; Olecki, Elizabeth J; Sellers, Jacob A; Kuchimanchi, Nidhi; Dengel, Lynn T; Slingluff, Craig L Jr; Witt, Russell G

Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy

维莫非尼±考比替尼对BRAFV600突变型黑色素瘤患者肿瘤内免疫和宿主免疫的影响:与免疫疗法联合应用的意义

Rapisuwon, Suthee; Slingluff, Craig L Jr; Wargo, Jennifer A; Sullivan, Ryan J; Izar, Benjamin; Lin, Jia-Ren; Mauldin, Ileana S; Olson, Walter C; Tran, Christine A; Schwartzman, Gabrielle H; Gibney, Geoffrey T; Al-Refaie, Waddah; Atkins, Michael B

Addendum: Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial

附录:多肽疫苗在黑色素瘤辅助治疗中的应用:一项随机 II 期试验的长期生存结果和事后分析

Ninmer, Emily K; Zhu, Hong; Chianese-Bullock, Kimberly A; von Mehren, Margaret; Haas, Naomi B; Ross, Merrick I; Dengel, Lynn T; Slingluff, Craig L Jr

Where You Train Matters: Surgeon-Scientists Disproportionately Trained at Highly Funded Institutions

受训地点至关重要:外科医生科学家大多在资金雄厚的机构接受培训

Mayhew, Mackenzie M; Kuchimanchi, Nidhi; Lee, Justin; Olecki, Elizabeth J; Sellers, Jacob; Slingluff, Craig L Jr; Tsung, Allan; Witt, Russell G

Twenty-year survival outcomes after multipeptide vaccination for resected high-risk melanoma: A post-hoc analysis of a randomized clinical trial

多肽疫苗接种治疗切除的高危黑色素瘤患者的20年生存结果:一项随机临床试验的事后分析

Ninmer, Emily K; Zhu, Hong; Chianese-Bullock, Kimberly A; Slingluff, Craig L Jr

The Landmark Series: Cancer Vaccines for Solid Tumors

里程碑系列:实体瘤癌症疫苗

Ninmer, Emily K; Xu, Feifan; Slingluff, Craig L Jr